AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26712188 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous dilatational tracheostomy without fiberoptic bronchoscopy (Group A)
Number of subjects: 60
Study 24748400 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-nitrous oxide
Number of subjects: 100
Study 24748400 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane-nitrous oxide
Number of subjects: 100
Study 22771137 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezogabine/retigabine
Number of subjects: 336
Study 20683947 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ursodeoxycholic acid (UDCA) 23-28 mg/kg/day
Number of subjects: 185
Study 20683947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 17630563 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor-based antiretroviral therapy
Number of subjects: 379
Study 17630563 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (general)
Number of subjects: 379
Study 17630563 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV genotype 1 or 4 infection
Number of subjects: 379
Study 15677384 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 15677384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12697595 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 15 mg plus morphine 150 micro g (RM group)
Number of subjects: 50
Study 12697595 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 15 mg plus morphine 150 micro g (BM group)
Number of subjects: 50
Study 12697595 — intervention group
Group type: COMPARATOR
Intervention: Both groups (RM and BM)
Number of subjects: 50
Study 10823363 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum (LI 160) 600 mg/d for 1 week, then 900 mg/d for 6 weeks
Number of subjects: 30
Study 10823363 — intervention group
Group type: COMPARATOR
Intervention: Sertraline 50 mg/d for 1 week, then 75 mg/d for 6 weeks
Number of subjects: 30
Study 9032863 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose Gamma Knife treatment (surface dose 58 +/- 9 Gy, maximum dose 81 +/- 15 Gy, mean dose 66 +/- 11 Gy) in Group A (10 patients, follow-up 24 +/- 4 months)
Number of subjects: 36
Study 9032863 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose Gamma Knife treatment (surface dose 41 +/- 3 Gy, maximum dose 76 +/- 10 Gy, mean dose 53 +/- 11 Gy) in Group B (9 patients, follow-up 16 +/- 2 months)
Number of subjects: 36
Study 9032863 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose Gamma Knife treatment (surface dose 42 +/- 3 Gy, maximum dose 72 +/- 16 Gy, mean dose 54 +/- 6 Gy) in Group C (17 patients, follow-up 6 +/- 3 months)
Number of subjects: 36
Study 1523880 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugate vaccine (11 micrograms of each oligosaccharide and 88 micrograms of CRM 197)
Number of subjects: 0
Study 1523880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6389288 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine-papaverine combination (3 X 1 coated tablet per day for four weeks)
Number of subjects: 0
Study 6389288 — intervention group
Group type: COMPARATOR
Intervention: Papaverine alone
Number of subjects: 0
Study 6389288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2867260 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg aspirin daily
Number of subjects: 46
Study 2867260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 30714482 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered therapy using a smart tablet (trained with functional words)
Number of subjects: 5
Study 30714482 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered therapy using a smart tablet (trained with words from a picture database)
Number of subjects: 5
Study 30714482 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered therapy using a smart tablet (exposed but not trained)
Number of subjects: 5
Study 30714482 — intervention group
Group type: COMPARATOR
Intervention: Control group (not exposed)
Number of subjects: 5
Study 29799130 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection
Number of subjects: 27
Study 29799130 — intervention group
Group type: COMPARATOR
Intervention: Tumor incision (sham surgery)
Number of subjects: 27
Study 29799130 — intervention group
Group type: COMPARATOR
Intervention: Macroscopic complete resection (MCR) in patients
Number of subjects: 27
Study 28102427 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg intravenous acetylsalicylic acid (ASA)
Number of subjects: 270
Study 28102427 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg intravenous acetylsalicylic acid (ASA)
Number of subjects: 270
Study 28102427 — intervention group
Group type: COMPARATOR
Intervention: 300 mg oral acetylsalicylic acid (ASA)
Number of subjects: 270
Study 25692350 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-dose Zagreb regimen
Number of subjects: 600
Study 25692350 — intervention group
Group type: COMPARATOR
Intervention: 5-dose Essen regimen
Number of subjects: 600
Study 23835708 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus pemetrexed 500 mg/m(2)
Number of subjects: 376
Study 23835708 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab 7.5 mg/kg
Number of subjects: 376
Study 20042475 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate 50 mg kg(‐1) i.v. as a bolus and 15 mg kg(‐1) h(‐1) by continuous infusion during the operation
Number of subjects: 61
Study 20042475 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 61
Study 19032711 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifamily group therapy plus pharmacotherapy
Number of subjects: 53
Study 19032711 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual family therapy plus pharmacotherapy
Number of subjects: 53
Study 19032711 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy alone
Number of subjects: 53
Study 16595599 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1 g twice daily)
Number of subjects: 28
Study 16595599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 11799338 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg/day, increased to 100 mg after 4 weeks if inadequate response)
Number of subjects: 48
Study 11799338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 9718016 — intervention group
Group type: EXPERIMENTAL
Intervention: Active suction drainage
Number of subjects: 101
Study 9718016 — intervention group
Group type: COMPARATOR
Intervention: Passive chest drainage
Number of subjects: 101
Study 9718016 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 101
Study 7917732 — intervention group
Group type: EXPERIMENTAL
Intervention: Active skin surface warming (forced heated air, Bair‐Hugger)
Number of subjects: 45
Study 7917732 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive skin surface warming (metallized plastic sheet, Thermolite)
Number of subjects: 45
Study 7917732 — intervention group
Group type: COMPARATOR
Intervention: Control (no intraoperative warming device)
Number of subjects: 45
Study 2779240 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.125 g/kg of 95% ethanol)
Number of subjects: 6
Study 2779240 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.25 g/kg of 95% ethanol)
Number of subjects: 6
Study 2779240 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.5 g/kg of 95% ethanol)
Number of subjects: 6
Study 2779240 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent schedule of point presentation
Number of subjects: 6
Study 2779240 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between alcohol and concurrent point presentation contingencies
Number of subjects: 6
Study 2779240 — intervention group
Group type: COMPARATOR
Intervention: No alcohol (0 g/kg of 95% ethanol)
Number of subjects: 6
Study 177873 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation with high-dose metronidazole
Number of subjects: 36
Study 177873 — intervention group
Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 36
Study 30032673 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg bilastine
Number of subjects: 33
Study 30032673 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg cetirizine
Number of subjects: 33
Study 30032673 — intervention group
Group type: COMPARATOR
Intervention: 20 mg pyridoxine (placebo)
Number of subjects: 33
Study 25983332 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of health promotion (HP), occupational health and safety (OHS), and kaizen
Number of subjects: 12
Study 25983332 — intervention group
Group type: COMPARATOR
Intervention: Control group (no integration of HP, OHS, and kaizen)
Number of subjects: 12
Study 24854755 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifting gasless laparoscopic myomectomy with 5 mm laparoscope and 2 abdominal holes
Number of subjects: 90
Study 24854755 — intervention group
Group type: COMPARATOR
Intervention: Pneumoperitoneum laparoscopic myomectomy
Number of subjects: 90
Study 22049171 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control
Number of subjects: 0
Study 22049171 — intervention group
Group type: COMPARATOR
Intervention: Standard glycemic control
Number of subjects: 0
Study 22049171 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 0
Study 22049171 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure control
Number of subjects: 0
Study 22049171 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 0
Study 22049171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20464816 — intervention group
Group type: EXPERIMENTAL
Intervention: Older pilots (41+ years)
Number of subjects: 72
Study 20464816 — intervention group
Group type: COMPARATOR
Intervention: Younger pilots (under 41 years)
Number of subjects: 72
Study 20464816 — intervention group
Group type: EXPERIMENTAL
Intervention: Older IFR/CFI pilots
Number of subjects: 72
Study 20464816 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger IFR/CFI pilots
Number of subjects: 72
Study 20464816 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger CFII/ATP pilots
Number of subjects: 72
Study 20464816 — intervention group
Group type: EXPERIMENTAL
Intervention: Older CFII/ATP pilots
Number of subjects: 72
Study 20464816 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilots with faster processing speed
Number of subjects: 72
Study 20464816 — intervention group
Group type: COMPARATOR
Intervention: Pilots with slower processing speed
Number of subjects: 72
Study 18666223 — intervention group
Group type: EXPERIMENTAL
Intervention: alb-IFN 900 microg q2wk
Number of subjects: 458
Study 18666223 — intervention group
Group type: EXPERIMENTAL
Intervention: alb-IFN 1200 microg q2wk
Number of subjects: 458
Study 18666223 — intervention group
Group type: EXPERIMENTAL
Intervention: alb-IFN 1200 microg q4wk
Number of subjects: 458
Study 18666223 — intervention group
Group type: COMPARATOR
Intervention: PEG-IFNalpha-2a 180 microg qwk
Number of subjects: 458
Study 18666223 — intervention group
Group type: COMPARATOR
Intervention: PEG-IFNalpha-2a
Number of subjects: 458
Study 15769244 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who overheard peers discussing a fair reputation
Number of subjects: 105
Study 15769244 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who overheard peers discussing an unfair reputation
Number of subjects: 105
Study 15769244 — intervention group
Group type: COMPARATOR
Intervention: Participants who heard no prior information about the experimenter
Number of subjects: 105
Study 12799881 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical and surgical treatment for GERD
Number of subjects: 0
Study 12799881 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 10780828 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol preload
Number of subjects: 22
Study 10780828 — intervention group
Group type: EXPERIMENTAL
Intervention: Juice preload
Number of subjects: 22
Study 10780828 — intervention group
Group type: COMPARATOR
Intervention: Water control
Number of subjects: 22
Study 7718367 — intervention group
Group type: EXPERIMENTAL
Intervention: i.m. ketorolac 30 mg
Number of subjects: 0
Study 7718367 — intervention group
Group type: COMPARATOR
Intervention: morphine 10 mg
Number of subjects: 0
Study 7718367 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 0
Study 2074061 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological preparation (cognitive-behavioral program, 'stress inoculation')
Number of subjects: 40
Study 2074061 — intervention group
Group type: COMPARATOR
Intervention: Attention-placebo group (control)
Number of subjects: 40
Study 7006805 — intervention group
Group type: EXPERIMENTAL
Intervention: ICRF‐159
Number of subjects: 37
Study 7006805 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU
Number of subjects: 37
Study 7006805 — intervention group
Group type: EXPERIMENTAL
Intervention: ICRF‐159 (crossover after 5‐FU)
Number of subjects: 37
Study 7006805 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU (crossover after ICRF‐159)
Number of subjects: 37
Study 27237762 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified clinical Pilates exercises (2 times a week for 10 weeks)
Number of subjects: 11
Study 27237762 — intervention group
Group type: COMPARATOR
Intervention: Healthy matched controls
Number of subjects: 11
Study 24045635 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea purpurea (ECH) 8,000 mgd(‐1) for 6 weeks
Number of subjects: 16
Study 24045635 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) wheat flour for 6 weeks
Number of subjects: 16
Study 22104568 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) intervention
Number of subjects: 41
Study 22104568 — intervention group
Group type: COMPARATOR
Intervention: Wait‐list control
Number of subjects: 41
Study 20032007 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (200 mg three times per week)
Number of subjects: 49
Study 20032007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 16845552 — intervention group
Group type: EXPERIMENTAL
Intervention: WMSD patients
Number of subjects: 61
Study 16845552 — intervention group
Group type: EXPERIMENTAL
Intervention: WAD patients
Number of subjects: 61
Study 16845552 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 61
Study 16845552 — intervention group
Group type: EXPERIMENTAL
Intervention: WMSD and WAD patients
Number of subjects: 61
Study 15947534 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate XVE Left Ventricular Assist Device (LVAD)
Number of subjects: 42
Study 11837717 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil alfadex at a dose of 0.05 microg/kg/min
Number of subjects: 20
Study 11837717 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil alfadex at a dose of 0.1 microg/kg/min
Number of subjects: 20
Study 11837717 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 20
Study 10368359 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (1.2 g/day for 3 days)
Number of subjects: 16
Study 10368359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10368359 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 16
Study 10368359 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen and Placebo
Number of subjects: 16
Study 8712438 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique 1 (SIB compressed before connection)
Number of subjects: 54
Study 8712438 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique 2 (SIB compressed after connection)
Number of subjects: 54
Study 8712438 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique 2 (after delivery of three breaths)
Number of subjects: 54
Study 1817935 — intervention group
Group type: EXPERIMENTAL
Intervention: One-step excavation of deep carious lesions
Number of subjects: 0
Study 1817935 — intervention group
Group type: COMPARATOR
Intervention: Stepwise method
Number of subjects: 0
Study 1817935 — intervention group
Group type: EXPERIMENTAL
Intervention: Histology (both methods)
Number of subjects: 0
Study 1817935 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiological examination
Number of subjects: 0
Study 1817935 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pulp inflammations
Number of subjects: 0
Study 1817935 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammation-free pulps
Number of subjects: 0
Study 6897860 — intervention group
Group type: EXPERIMENTAL
Intervention: DOPP (doxorubicin, oncovin, procarbazine and prednisolone)
Number of subjects: 37
Study 6897860 — intervention group
Group type: COMPARATOR
Intervention: MOPP (mustine, oncovin, procarbazine and prednisolone)
Number of subjects: 37
Study 31606244 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (840 mg EPA and 560 mg DHA per day)
Number of subjects: 0
Study 31606244 — intervention group
Group type: COMPARATOR
Intervention: Placebo (paraffin oil)
Number of subjects: 0
Study 30206011 — intervention group
Group type: EXPERIMENTAL
Intervention: HeProCalc algorithm
Number of subjects: 210
Study 30206011 — intervention group
Group type: COMPARATOR
Intervention: Traditional heparin and protamine dosage based on body weight (Control group)
Number of subjects: 210
Study 29232964 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Finding intervention
Number of subjects: 568
Study 26919870 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure target (<130 mm Hg or 10 mm Hg reduction from baseline if this was <140 mm Hg)
Number of subjects: 529
Study 26919870 — intervention group
Group type: COMPARATOR
Intervention: Standard target (<140 mm Hg)
Number of subjects: 529
Study 24060523 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (ARB group)
Number of subjects: 48
Study 24060523 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (CCB group)
Number of subjects: 48
Study 22156892 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (20 μg/h)
Number of subjects: 22
Study 22156892 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (25 μg/h)
Number of subjects: 22
Study 22156892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 20676814 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading within the first week after insertion
Number of subjects: 41
Study 20676814 — intervention group
Group type: COMPARATOR
Intervention: Conventional loading after a 12-week healing phase
Number of subjects: 41
Study 20676814 — intervention group
Group type: EXPERIMENTAL
Intervention: Both loading groups
Number of subjects: 41
Study 20676814 — intervention group
Group type: COMPARATOR
Intervention: Conventional loading
Number of subjects: 41
Study 20676814 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading
Number of subjects: 41
Study 17343594 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen-polyvinylpyrrolidone (clg-pvp) applied at a rate of 1.5 ml intradermically at four equi-spaced points around the ulcer.
Number of subjects: 0
Study 17343594 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution with polyvinylpyrrolidone) applied at a rate of 1.5 ml intradermically at four equi-spaced points around the ulcer.
Number of subjects: 0
Study 15766828 — intervention group
Group type: EXPERIMENTAL
Intervention: Snuff tobacco
Number of subjects: 16
Study 15766828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12108897 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m2 (D75)
Number of subjects: 577
Study 12108897 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m2 (D100)
Number of subjects: 577
Study 12108897 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine/Ifosfamide (V/I)
Number of subjects: 577
Study 10468470 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dimensional tuned-aperture computed tomography (TACT)
Number of subjects: 0
Study 10468470 — intervention group
Group type: COMPARATOR
Intervention: Conventional periapical and/or panoramic radiographs
Number of subjects: 0
Study 8315700 — intervention group
Group type: EXPERIMENTAL
Intervention: Day hospital program
Number of subjects: 0
Study 8315700 — intervention group
Group type: COMPARATOR
Intervention: Inpatient program
Number of subjects: 0
Study 3808504 — intervention group
Group type: EXPERIMENTAL
Intervention: strict management (euglycemic: fasting blood glucose < 80 mg/dL, 1.5-hour postprandial blood glucose < 120 mg/dL)
Number of subjects: 254
Study 3808504 — intervention group
Group type: EXPERIMENTAL
Intervention: customary management (fasting blood glucose ≤ 100 mg/dL, postprandial blood glucose < 140 mg/dL)
Number of subjects: 254
Study 3808504 — intervention group
Group type: EXPERIMENTAL
Intervention: management identical to customary management (for group III)
Number of subjects: 254
Study 3808504 — intervention group
Group type: COMPARATOR
Intervention: Control group (infants of nondiabetic mothers)
Number of subjects: 254
Study 30269060 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms measured by the Center for Epidemiologic Studies Depression scale
Number of subjects: 1359
Study 30269060 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor academic performance
Number of subjects: 1359
Study 30269060 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher consumption of unhealthy food
Number of subjects: 1359
Study 30269060 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative self-perception about body shape
Number of subjects: 1359
Study 30269060 — intervention group
Group type: EXPERIMENTAL
Intervention: General health status
Number of subjects: 1359
Study 30269060 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited physical activeness
Number of subjects: 1359
Study 30269060 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse childhood experiences including physical violence
Number of subjects: 1359
Study 30269060 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological abuse during childhood
Number of subjects: 1359
Study 30269060 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of general and medical care by family during childhood
Number of subjects: 1359
Study 27073975 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management
Number of subjects: 0